Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Japanese Firms Link With U.S. Institutes
by Michael McCoy
April 13, 2015
| A version of this story appeared in
Volume 93, Issue 15
Two Japanese drug companies have signed R&D pacts with U.S. research institutes. Astellas Pharma will work with the University of Texas MD Anderson Cancer Center on a new treatment for patients with acute myeloid leukemia. The pact, which includes a payment of up to $26 million by Astellas, will focus on h8F4, a humanized monoclonal antibody invented by MD Anderson professor Jeffrey J. Molldrem. Daiichi Sankyo, meanwhile, will work with California’s Sanford-Burnham Medical Research Institute to develop a small-molecule cardiovascular-metabolic disease treatment that arose from work by a Sanford-Burnham scientist.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter